Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus

Blood

Volumn 97, Issue 10, 2001, Pages 3244-3250

  Davis, David A ^a   Rinderknecht, Andrea S ^a   Paul Zoeteweij, J ^a   Aoki, Yoshiyasu ^a   Read Connole, Elizabeth L ^a   Tosato, Giovanna ^a   Blauvelt, Andrew ^a   Yarchoan, Robert ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COBALT CHLORIDE; DEFEROXAMINE; HYPOXIA INDUCIBLE FACTOR 1; INTERLEUKIN 6; PHORBOL 13 ACETATE 12 MYRISTATE;

ARTICLE; CYTOKINE RELEASE; HUMAN HERPESVIRUS 8; HYPOXIA; KAPOSI SARCOMA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS DETECTION; VIRUS REPLICATION; WESTERN BLOTTING;

EID: 0035874496     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.10.3244     Document Type: Article

References (51)

1. Longo DL, Steis RG, Lane HC, et al. Malignancies in the AIDS patient: natural history, treatment strategies, and preliminary results. Ann N Y Acad Sci. 1984;437:421-430.
2. Dupin N, Fisher C, Kellam P, et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A. 1999;96:4546-4551.
3. Antman K, Chang Y. Kaposi's sarcoma. N Engl J Med. 2000;342:1027-1038.
4. Iscovich J, Boffetta P, Franceschi S, Azizi E, Sarid R. Classic Kaposi sarcoma: epidemiology and risk factors. Cancer. 2000;88:500-517.
5. Stein ME, Spencer D, Ruff P, Lakier R, MacPhail P, Bezwoda WR. Endemic African Kaposi's sarcoma: clinical and therapeutic implications: 10-year experience in the Johannesburg Hospital (1980-1990). Oncology. 1994;51:63-69.
6. Friedman-Kien AE, Saltzman BR. Clinical manifestations of classical, endemic African, and epidemic AIDS-associated Kaposi's sarcoma. J Am Acad Dermatol. 1990;22:1237-1250.
7. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994;266:1865-1869.
8. Whitby D, Howard MR, Tenant-Flowers M, et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet. 1995;346:799-802.
9. Gao SJ, Kingsley L, Li M, et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med. 1996;2:925-928.
10. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med. 1995;332:1186-1191.
11. Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N Engl J Med. 1995;332:1181-1185.
12. Chuck S, Grant RM, Katongole-Mbidde E, Conant M, Ganem D. Frequent presence of a novel herpesvirus genome in lesions of human immunodeficiency virus-negative Kaposi's sarcoma. J Infect Dis. 1996;173:248-251.
13. Boshoff C, Endo Y, Collins PD, et al. Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science. 1997;278:290-294.
14. Nicholas J, Ruvolo VR, Burns WH, et al. Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6. Nat Med. 1997;3:287-292.
15. Neipel F, Albrecht JC, Ensser A, et al. Human herpesvirus 8 encodes a homolog of interleukin-6. J Virol. 1997;71:839-842.
16. Moore PS, Boshoff C, Weiss RA, Chang Y. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science. 1996;274:1739-1744.
17. Kaposi M. Idiopathic multiple pigmented sarcoma of the skin. CA Cancer J Clin. 1982;32:342-347.
18. Ubbink DT, Tulevski II, den Hartog D, Koelemay MJ, Legemate DA, Jacobs MJ. The value of noninvasive techniques for the assessment of critical limb ischaemia. Eur J Vasc Endovasc Surg. 1997;13:296-300.
19. Renne R, Zhong W, Herndier B, et al. Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med. 1996;2:342-346.
20. Arvanitakis L, Mesri EA, Nador RG, et al. Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. Blood. 1996;88:2648-2654.
21. Zoeteweij JP, Eyes ST, Orenstein JM, et al. Identification and rapid quantification of early- and late-lytic human herpesvirus 8 infection in single cells by flow cytometric analysis: characterization of antiherpesvirus agents. J Virol. 1999;73:5894-5902.
22. Davis DA, Humphrey RW, Newcomb FM, et al. Detection of serum antibodies to a Kaposi's sarcoma-associated herpesvirus-specific peptide. J Infect Dis. 1997;175:1071-1079.
23. Aoki Y, Yarchoan R, Braun J, Iwamoto A, Tosato G. Viral and cellular cytokines in AIDS-related malignant lymphomatous effusions. Blood. 2000;96:1599-1601.
24. Sarid R, Flore O, Bohenzky RA, Chang Y, Moore PS. Transcription mapping of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1), J Virol. 1998;72:1005-1012.
25. Aoki Y, Tosato G. Role of vascular endothelial growth factor/vascular permeability factor in the pathogenesis of Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphomas. Blood. 1999;94:4247-4254.
26. Molden J, Chang Y, You Y, Moore PS, Goldsmith MA. A Kaposi's sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit. J Biol Chem. 1997;272:19625-19631.
27. Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol. 1999;15:551-578.
28. Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood. 1993;82:3610-3615.
29. Jiang BH, Semenza GL, Bauer C, Marti HH. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol. 1996;271:C1172-1180.
30. Chang N, Goodson WH, Gottrup F, Hunt TK. Direct measurement of wound and tissue oxygen tension in postoperative patients. Ann Surg. 1983;197:470-478.
31. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol. 2000;88:1474-1480.
32. Lantsberg L, Goldman M. Laser Doppler flowmetry, transcutaneous oxygen tension measurements and Doppler pressure compared in patients undergoing amputation. Eur J Vasc Surg. 1991;5:195-197.
33. Richard DE, Berra E, Pouyssegur J. Angiogenesis: how a tumor adapts to hypoxia. Biochem Biophys Res Commun. 1999;266:718-722.
34. Semenza GL. Perspectives on oxygen sensing. Cell. 1999;98:281-284.
35. Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem. 1994;269:23757-23763.
36. Liu Y, Cox SR, Morita T, Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells: identification of a 5′ enhancer. Circ Res. 1995;77:638-643.
37. Lukac DM, Kirshner JR, Ganem D. Transcriptional activation by the product of open reading frame 50 of Kaposi's sarcoma-associated herpesvirus is required for lytic viral reactivation in B cells. J Virol. 1999;73:9348-93461.
38. Masood R, Cai J, Zheng T, Smith DL, Naidu Y, Gill PS. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc Natl Acad Sci U S A. 1997;94:979-984.
39. Bais C, Santomasso B, Coso O, et al. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature. 1998;391:86-89.
40. Ebbesen P, Toth FD, Villadsen JA, Norskov-Lauritsen N. In vitro interferon and virus production at in vivo physiologic oxygen tensions. In Vivo. 1991;5:355-358.
41. Lee SW, Lee YM, Bae SK, Murakami S, Yun Y, Kim KW. Human hepatitis B virus X protein is a possible mediator of hypoxia-induced angiogenesis in hepatocarcinogenesis. Biochem Biophys Res Commun. 2000;268:456-461.
42. Rabkin CS, Janz S, Lash A, et al. Monoclonal origin of multicentric Kaposi's sarcoma lesions. N Engl J Med. 1997;336:988-993.
43. Ensoli B, Barillari G, Gallo RC. Cytokines and growth factors in the pathogenesis of AIDS-associated Kaposi's sarcoma. Immunol Rev. 1992;127:147-155.
44. Yarchoan R. Therapy for Kaposi's sarcoma: recent advances and experimental approaches. J Acquir Immune Defic Syndr. 1999;21(suppl 1):S66-S73.
45. Miles SA, Rezai AR, Salazar-Gonzalez JF, et al.: AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci U S A. 1990;87:4068-4072.
46. Laor Y, Schwartz RA. Epidemiologic aspects of American Kaposi's sarcoma. J Surg Oncol. 1979;12:299-303.
47. Friedman-Birnbaum R, Welffriend S, Katz I. Kaposi's sarcoma: retrospective study of 67 cases with the classical form. Dermatologica. 1990;180:13-17.
48. Cook PM, Whitby D, Calabro ML, et al. Variability and evolution of Kaposi's sarcoma-associated herpesvirus in Europe and Africa. International Collaborative Group. AIDS. 1999;13:1165-1176.
49. Simpson GR, Schulz TF, Whitby D, et al. Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet. 1996;348:1133-1138.
50. Sarid R, Olsen SJ, Moore PS. Kaposi's sarcoma-associated herpesvirus: epidemiology, virology, and molecular biology. Adv Virus Res. 1999;52:139-232.
51. Franceschi S, Geddes M. Epidemiology of classic Kaposi's sarcoma, with special reference to Mediterranean population. Tumori. 1995;81:308-314.